Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase | Zendy

Mark Catherine | Zendy; Gupta Sumit | Zendy; Punnett Angela | Zendy; Upton Julia | Zendy; Orkin Julia | Zendy; Atkinson Adelle | Zendy; Clarke Lindsay | Zendy; Heisey Alice | Zendy; McGovern Christine | Zendy; Alexander Sarah | Zendy

Premium

Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase

Author(s) -

Mark Catherine,

Gupta Sumit,

Punnett Angela,

Upton Julia,

Orkin Julia,

Atkinson Adelle,

Clarke Lindsay,

Heisey Alice,

McGovern Christine,

Alexander Sarah

Publication year - 2021

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.29295

Subject(s) - medicine , peg ratio , vaccination , asparaginase , lymphoblastic leukemia , allergy , pediatrics , immunology , leukemia , finance , economics

Vaccinationis a critical tool in the prevention of COVID‐19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently, in North America, only the BNT162b2 (Pfizer‐BioNTech ) mRNA vaccine is approved for individuals aged 12–17. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive PEG‐asparaginase (PEG‐ASNase) and 10%–30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients is critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG‐ASNase allergy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research